MTOR and lung adenocarcinoma: Notably, co-mutations in EGFR and PIK3CA could reflect crosstalk between the EGFR and PI3K-AKT-mTOR pathways, potentially indicating poor prognosis in advanced EGFR-mutant lung adenocarcinomas [40,41].